ALFA Finder| Value | ₹9.38 Cr |
|---|
NSE filing, NSE: ZYDUSLIFE. Summary written from the filing by ALFA Finder's alert engine.
Zydus Lifesciences Ltd: key numbers
- Share price
- ₹1,199.60
- Market cap
- ₹1,20,708 Cr
- Revenue (annual)
- ₹27,148 Cr
- Net profit (annual)
- ₹5,040 Cr
- P/E (TTM)
- 28.9×Sector 43.8×
- Promoter holding
- 75.01%+0.00% QoQ
- FII holding
- 7.05%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Zydus Lifesciences Ltd
All →Zydus Lifesciences Merger & Restructuring
Zydus completed its subscription for 50% of Zydus Sunshine, making it a 50:50 joint venture with Sunshine Healthcare Lanka. Completed November 11, 2026.
Zydus Lifesciences Capital Structure Change
LIC sold 20,242,068 Zydus Lifesciences shares via market sale, cutting its stake from 5.21 percent to 3.18 percent. Non-promoter SAST disclosure covering 28.08.2025 to 05.11.2026.
Zydus Lifesciences Business Update
Zydus Lifesciences' subsidiary presented Phase 2b trial data for investigational saroglitazar in MASH at AASLD 2026. The drug showed higher steatohepatitis resolution than placebo, but its safety and effectiveness for this use are not yet established.
Zydus Lifesciences Earnings Call Transcript: Key Takeaways
Consolidated revenue ₹7,910 Cr (+29% YoY), EBITDA margin 24%, net profit ₹930 Cr. Growth partly acquisition-led. Saroglitazar launch spend is heavy and the US launch is targeted for March 2027.
Zydus Lifesciences Results Update
Zydus Lifesciences reported Q2 FY27 revenue of Rs. 79,096 mn, up 29% y-o-y. H1 net profit was Rs. 18,859 mn, down 31%.
Zydus Lifesciences Investor Presentation: Key Takeaways
Q2 FY27 revenue Rs 7,910 Cr (+29% YoY), EBITDA Rs 1,895 Cr at 24.0% margin, reported PAT Rs 926 Cr (-26.6% YoY). Branded India and North America drove growth; FX and D&A weighed on profit.
Other merger & restructuring announcements
All →Spacenet Enterprises India Merger & Restructuring Worth ₹2.6 Cr
Spacenet sold 40,00,005 String Metaverse shares on 11 November 2026 at ₹6.49 each. Gross consideration of about ₹2.60 Crore is disclosed as material.
- Value
- ₹2.60 Cr
Abans Financial Services Merger & Restructuring Worth ₹1.2 Cr
Abans Financial Services approved incorporating a Hong Kong subsidiary for bullion and securities trading. The cash consideration is Rs 1.20 Crore.
- Value
- ₹1.20 Cr
Adani Enterprises Merger & Restructuring Worth ₹0.94 Cr
Adani Enterprises reported incorporation of Adani Rovuma Chemicals Limited in UAE on November 10, 2026, via Adani Global Limited. Cash consideration of Rs. 0.94 Crore was stated.
- Value
- ₹0.94 Cr
Adani Enterprises Merger & Restructuring
Adani Enterprises' subsidiary Adani Global incorporated Adani Rovuma Chemicals Limited in UAE on November 10, 2026. It is a step-down subsidiary with USD 100,000 paid-up capital.
Kovai Medical Center and Hospital Merger & Restructuring Worth ₹0.85 Cr
Kovai Medical extended the completion deadline for the slump sale of its AHS division to a related-party trust to January 31, 2027. Cash consideration is Rs.84.54 Lakhs.
- Value
- ₹0.85 Cr
- Execution
- Completion expected by 31 January 2027
Gita Renewable Energy Merger & Restructuring
Gita Renewable Energy's board approved becoming a 5% partner in Penthouse Properties LLP, a non-related entity. The company will contribute 22,05,022 Manaksia Coated Metals shares as capital, about 2.08% of that company.